DiaMedica Therapeutics Announces Appointment of Dr. Richard Kuntz to the Board of Directors

Author's Avatar
May 30, 2023

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on acute ischemic stroke and other vascular diseases, today announced the appointment of Dr. Richard Kuntz to its Board of Directors effective May 30, 2023.